BCAX
Bicara Therapeutics Inc. Common Stock · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -7.1% ·
aandelenstroom +2.2% ·
netto nieuwe posities -15.4%
— formule
Geconcentreerde accumulatie — stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | +5 | 22.18M | $657.51M | +10 | −5 |
| Q1 2026 | 68 | +4 | 22.46M | $446.36M | +8 | −5 |
| Q4 2025 | 65 | 0 | 22.60M | $380.21M | +3 | −2 |
| Q3 2025 | 13 | -1 | 12.02M | $189.85M | — | −2 |
| Q2 2025 | 12 | 0 | 11.43M | $106.16M | +3 | −3 |
| Q1 2025 | 9 | +1 | 5.34M | $69.55M | +2 | −1 |
| Q4 2024 | 8 | -3 | 5.77M | $100.60M | +1 | −4 |
| Q3 2024 | 10 | +10 | 4.16M | $105.86M | +10 | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 2.70M | +6.3% | $42.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 2.70M | +6.3% | $42.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 2.70M | +6.3% | $42.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 2.70M | +6.3% | $42.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 2.70M | +6.3% | $42.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | BlackRock ✦ (passief) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passief) | 2.20M | +9.8% | $34.75M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passief) | 2.20M | +9.8% | $34.75M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | The Vanguard Group ✦ (passief) | 2.20M | +9.8% | $34.75M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 1.76M | -18.4% | $27.72M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 1.76M | -18.4% | $27.72M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Millennium Management ✦ | 1.01M | +37.0% | $16.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 20 | Geode Capital Management ✦ (passief) | 831.21K | +23.6% | $13.13M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Geode Capital Management ✦ (passief) | 831.21K | +23.6% | $13.13M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | State Street Global Advisors ✦ (passief) | 590.28K | +9.1% | $9.32M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Goldman Sachs Group ✦ | 232.76K | — | $3.68M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Goldman Sachs Group ✦ | 232.76K | — | $3.68M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Marshall Wace ✦ | 112.09K | +116.3% | $1.77M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 26 | Marshall Wace ✦ | 112.09K | +116.3% | $1.77M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | Two Sigma Investments ✦ | 95.24K | -29.2% | $1.50M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ |
| 40 | Point72 Asset Management ✦ | 30.14K | -86.1% | $475,885 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Citadel Advisors | $2.06M | was 0.0% |
| Norges Bank | $398,439 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 146 houders, 71.07M aandelen, $1.23B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 18.75K aand · $524,533
Officer, Director · 10.00K aand · $279,750
Officer · 12.50K aand · $349,591
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie